Daniel C. Martin - Oct 28, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Oct 28, 2023
Transactions value $
-$16,909
Form type
4
Date filed
10/31/2023, 04:10 PM
Previous filing
Jun 21, 2023
Next filing
Dec 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award +5.58K +9.5% 64.3K Oct 28, 2023 Direct F1, F2
transaction DCPH Common Stock Sale -$16.9K -1.41K -2.19% $12.02 62.9K Oct 30, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 5,576 RSUs.
F2 Includes 302 shares previously acquired under the Issuer's 2017 Employee Stock Purchase Plan.
F3 This sale was to cover tax liabilities in the vesting of RSUs.